Draupnir Bio, a cutting-edge biotechnology company, has successfully raised €12 million in equity investments to advance its innovative approach in targeted protein degradation (TPD). This recent funding round, led by MP Healthcare and the Export and Investment Fund of Denmark (EIFO), marks a significant milestone for the company as it seeks to revolutionize the treatment of complex diseases by targeting extracellular proteins. This investment follows previous rounds, bringing the total funds raised by Draupnir Bio to approximately €42 million.
Background
Draupnir Bio was founded in 2017 as a spin-out from Aarhus University, Denmark, and the Max-Planck Society,
